MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02182375

Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer

Phase 1
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT02182102

A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer

Phase 1
Completed
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2014-07-08
Last Posted Date
2014-07-18
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
33
Registration Number
NCT02182232

Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers

First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
25
Registration Number
NCT02182531

WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis

Phase 3
Completed
Conditions
Rhinitis, Allergic, Perennial
Interventions
Drug: WAL801CL dry syrup
Drug: WAL 801 CL dry syrup placebo
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
151
Registration Number
NCT02182544

WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients

Phase 3
Completed
Conditions
Dermatitis, Atopic
Interventions
Drug: WAL 801 CL dry syrup
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
62
Registration Number
NCT02182570

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBT 1011 BS placebo
Drug: Single rising doses of BIBT 1011 BS
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
56
Registration Number
NCT02182037

Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: EE/NET
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
14
Registration Number
NCT02182791

Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma

Phase 3
Completed
Conditions
Asthma
Interventions
Drug: Berodual® MDI
Drug: Berodual® Respimat®, low dose
Drug: Berodual® Respimat®, high dose
First Posted Date
2014-07-08
Last Posted Date
2014-07-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
535
Registration Number
NCT02182505

Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy Recreational Sports People

Phase 2
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: Ginsana
First Posted Date
2014-07-08
Last Posted Date
2014-07-08
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT02182934
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy